Recombinant Human PD-1 Fc Chimera Protein, CF
Recombinant Human PD-1 Fc Chimera Protein, CF Summary
Why choose R&D Systems PD-1 Protein, Fc Chimera?
- Guaranteed Bioactivity and High Purity: Bioactivity tested by functional ELISA and purity determined by SDS-PAGE to be greater than 95%.
- Lot-to-Lot Consistency: Stringent QC testing performed on each lot to ensure consistent activity and purity.
- Bulk Quantities Available: Bulk up and save with large mass quantities to meet your research needs. Supply agreements available, partner with us. Please contact us.
- Most Respected, Most Cited Brand in Proteins: With over 35 years of providing the best recombinant proteins to the scientific community, R&D Systems continues to lead the industry in quality, activity, and purity.
Find the non-Fc, His-tagged PD-1 protein here PD-1 Protein His
Visit Bio-Techne to explore other immune checkpoint proteins Immune Checkpoint Proteins
Product Specifications
| Human PD-1 (Leu25-Gln167) Accession # Q15116.3 |
IEGRMD | Human IgG1 (Pro100-Lys330) |
| N-terminus | C-terminus | |
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
1086-PD
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 0.5 mg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
View Larger
Recombinant human PD-1/Fc (Catalog # 1086-PD) has a molecular weight (MW) of 125.1 kDa as analyzed by SEC-MALS, suggesting that this protein is a homodimer. MW may differ from predicted MW due to post-translational modifications (PTMs) present (i.e. Glycosylation).
View Larger
When Recombinant Human PD-1 Fc Chimera (Catalog # 1086-PD) is coated at 0.1 µg/mL, Recombinant Human B7-H1/PD-L1 Fc Chimera (156-B7) binds with a typical ED50 of 0.15-0.75 µg/mL.
Reconstitution Calculator
Background: PD-1
PD-1 (Programmed Death-1 receptor), also known as CD279, is a receptor expressed on T cells responsible for modulating T cell activation. Like CTLA‑4, PD-1 is classified as an immune checkpoint inhibitory receptor. When PD-1 protein binds to PD-L1, it initiates a negative signaling cascade inhibiting activation of T cells. The cytoplasmic tail contains two tyrosine residues that form the immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) that are important for mediating PD-1 signaling. Normally, PD-1 helps keep T cells from attacking other cells in the body. However, many cancers take advantage of this by expressing high amounts of PD-L1 allowing cancer cells to evade the body's own immune response. Blocking the PD-1:PD-L1 interaction has proven successful in treating many different cancer types.
PD-1 protein is type I transmembrane receptor belonging to the CD28 family of immune regulatory receptors (1). Other members of this family include CD28, CTLA‑4, ICOS, and BTLA (2-5). Mature human PD-1 consists of an extracellular region (ECD) with one immunoglobulin-like V‑type domain, a transmembrane domain, and a cytoplasmic region. The mature ECD of human PD-1 shares 61% amino acid sequence identity with mouse PD-1 ECD. PD-1 protein acts as a monomeric receptor and interacts in a 1:1 stoichiometric ratio with its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) (6, 7). PD‑1 is expressed on activated T cells, B cells, monocytes, and dendritic cells while PD-L1 expression is constitutive on the same cells and also on nonhematopoietic cells such as lung endothelial cells and hepatocytes (8, 9). Ligation of PD-L1 with PD-1 induces co-inhibitory signals on T cells promoting their apoptosis, anergy, and functional exhaustion (10). Thus, the PD-1:PD-L1 interaction is a key regulator of the threshold of immune response and peripheral immune tolerance (11).
- Ishida, Y. et al. (1992) EMBO J. 11:3887.
- Sharpe, A.H. and G.J. Freeman (2002) Nat. Rev. Immunol. 2:116.
- Coyle, A. and J. Gutierrez-Ramos (2001) Nat. Immunol. 2:203.
- Nishimura, H. and T. Honjo (2001) Trends Immunol. 22:265.
- Watanabe, N. et al. (2003) Nat. Immunol. 4:670.
- Zhang, X. et al. (2004) Immunity 20:337.
- Lázár-Molnár, E. et al. (2008) Proc. Natl. Acad. Sci. USA 105:10483.
- Nishimura, H. et al. (1996) Int. Immunol. 8:773.
- Keir, M.E. et al. (2008) Annu. Rev. Immunol. 26:677.
- Butte, M.J. et al. (2007) Immunity 27:111.
- Okazaki, T. et al. (2013) Nat. Immunol. 14:1212.
- Iwai, Y. et al. (2002) Proc. Natl. Acad. Sci. USA 99:12293.
- Nogrady, B. (2014) Nature 513:S10.
Citations for Recombinant Human PD-1 Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
39
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
The branched N-glycan of PD-L1 predicts immunotherapy responses in patients with recurrent/metastatic HNSCC
Authors: Huang, HC;Huang, YL;Chen, YJ;Wu, HY;Hsu, CL;Kao, HF;Liao, BC;Hsieh, MS;Lin, NY;Liao, YH;Chen, HL;Chen, CN;Chen, TC;Wang, CP;Yang, TL;Huang, MC;Lin, MC;Lou, PJ;
Oncogenesis
Species: Human
Sample Types: Cell Lysates
Applications: Bioassay -
Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interaction
Authors: Robinson, MA;Kennedy, A;Orozco, CT;Chen, HC;Waters, E;Giovacchini, D;Yeung, K;Filer, L;Hinze, C;Lloyd, C;Dovedi, SJ;Sansom, DM;
Cell reports
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption
Authors: Pereira Ribeiro, S;Strongin, Z;Soudeyns, H;Ten-Caten, F;Ghneim, K;Pacheco Sanchez, G;Xavier de Medeiros, G;Del Rio Estrada, PM;Pelletier, AN;Hoang, T;Nguyen, K;Harper, J;Jean, S;Wallace, C;Balderas, R;Lifson, JD;Raghunathan, G;Rimmer, E;Pastuskova, C;Wu, G;Micci, L;Ribeiro, RM;Chan, CN;Estes, JD;Silvestri, G;Gorman, DM;Howell, BJ;Hazuda, DJ;Paiardini, M;Sekaly, RP;
Nature immunology
Species: Rhesus Macaque
Sample Types: Serum
Applications: ELISA Capture -
CircRHBDD1 promotes immune escape via IGF2BP2/PD-L1 signaling and acts as a nanotherapeutic target in gastric cancer
Authors: Li, Y;Wang, Z;Gao, P;Cao, D;Dong, R;Zhu, M;Fei, Y;Zuo, X;Cai, J;
Journal of translational medicine
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer
Authors: Jeong, H;Koh, J;Kim, S;Song, SG;Lee, SH;Jeon, Y;Lee, CH;Keam, B;Lee, SH;Chung, DH;Jeon, YK;
British journal of cancer
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies
Authors: Manna, L;Rapuano Lembo, R;Yoshioka, A;Nakamura, K;Passariello, M;De Lorenzo, C;
Cancers
Species: Human
Sample Types: Antibody
Applications: Bioassay -
Clinical Staphylococcus aureus inhibits human T-cell activity through interaction with the PD-1 receptor
Authors: Mellergaard, M;Skovbakke, SL;Jepsen, SD;Panagiotopoulou, N;Hansen, ABR;Tian, W;Lund, A;Høgh, RI;Møller, SH;Guérillot, R;Hayes, AS;Erikstrup, LT;Andresen, L;Peleg, AY;Larsen, AR;Stinear, TP;Handberg, A;Erikstrup, C;Howden, BP;Goletz, S;Frees, D;Skov, S;
mBio
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry Control -
The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1
Authors: Erlichman, N;Meshel, T;Baram, T;Abu Raiya, A;Horvitz, T;Ben-Yaakov, H;Ben-Baruch, A;
Cells
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Influence on Soluble and Membrane Bound ICOS in Combination with Immune Checkpoint Blockade
Authors: Li, X;Li, J;Zheng, Y;Lee, SJ;Zhou, J;Giobbie-Hurder, A;Butterfield, LH;Dranoff, G;Hodi, FS;
Cancer immunology research
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development
Authors: T Phakham, C Boonkrai, T Wongtangpr, T Audomsun, C Attakitban, P Saelao, P Muanwien, S Sooksai, N Hirankarn, T Pisitkun
Scientific Reports, 2022-10-22;12(1):17792.
Species: Mouse
Sample Types: In Vivo
Applications: In Vivo -
Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs
Authors: Q Wang, Y Cao, L Shen, T Xiao, R Cao, S Wei, M Tang, L Du, H Wu, B Wu, Y Yu, S Wang, M Wen, B OuYang
Science Advances, 2022-08-26;8(34):eabq4722.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy
Authors: SS Ghaderi, F Riazi-Rad, ES Qamsari, S Bagheri, F Rahimi-Jam, Z Sharifzade
BMC biotechnology, 2022-08-23;22(1):22.
Species: Human
Sample Types: Phage
Applications: Bioassay -
D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
Authors: R Zhang, Y Yang, W Dong, M Lin, J He, X Zhang, T Tian, Y Yang, K Chen, QY Lei, S Zhang, Y Xu, L Lv
Proceedings of the National Academy of Sciences of the United States of America, 2022-02-22;119(8):.
Species: Human
Sample Types: Recombinant Proteins
Applications: Bioassay -
Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes
Authors: N Erlichman, T Baram, T Meshel, D Morein, B Da'adoosh, A Ben-Baruch
Cancers, 2022-02-18;14(4):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
Authors: CJ Edwards, A Sette, C Cox, B Di Fiore, C Wyre, D Sydoruk, D Yadin, P Hayes, S Stelter, PD Bartlett, M Zuazo, MJ Garcia-Gra, G Benedetti, S Fiaska, NR Birkett, Y Teng, C Enever, H Arasanz, A Bocanegra, L Chocarro, G Fernandez, R Vera, B Archer, I Osuch, M Lewandowsk, YM Surani, G Kochan, D Escors, J Legg, AJ Pierce
British Journal of Cancer, 2021-12-30;0(0):.
Species: Human
Sample Types: Protein
Applications: Bioassay -
TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity
Authors: Y Ren, Y Qian, L Ai, Y Xie, Y Gao, Z Zhuang, J Chen, YX Chen, JY Fang
Nature Communications, 2021-09-13;12(1):5405.
Species: Human
Sample Types: Whole Cells
Applications: Binding Assay -
Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments
Authors: C Vetrei, M Passariell, G Froechlich, R Rapuano Le, N Zambrano, C De Lorenzo
Cancers, 2021-06-08;13(12):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
Authors: JJ Park, EP Thi, VH Carpio, Y Bi, AG Cole, BD Dorsey, K Fan, T Harasym, CL Iott, S Kadhim, JH Kim, ACH Lee, D Nguyen, BS Paratala, R Qiu, A White, D Lakshminar, C Leo, RK Suto, R Rijnbrand, S Tang, MJ Sofia, CB Moore
Nature Communications, 2021-02-22;12(1):1222.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1
Authors: D Zhu, R Xu, X Huang, Z Tang, Y Tian, J Zhang, X Zheng
Cell Death and Differentiation, 2020-12-16;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity
Authors: C Li, H Yao, H Wang, JY Fang, J Xu
Oncogene, 2020-12-15;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Cell Culture -
Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity
Authors: N Silva-Pili, E Martisova, MC Ballestero, S Hervas-Stu, N Casares, G González-S, C Smerdou, L Vanrell
Biomedicines, 2020-12-02;8(12):.
Species: Human
Sample Types: Cell Culture Supernates, Recombinant Protein
Applications: Bioassay, ELISA Capture -
MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis
Authors: M Liberelle, R Magnez, X Thuru, Y Bencheikh, S Ravez, C Quenon, AS Drucbert, C Foulon, P Melnyk, IV Seuningen, N Lebègue
Sci Rep, 2019-11-13;9(1):16678.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
Authors: M Passariell, AM D'Alise, A Esposito, C Vetrei, G Froechlich, E Scarselli, A Nicosia, C De Lorenzo
Sci Rep, 2019-09-11;9(1):13125.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Upregulation of PD-L1 via HMGB1-activated IRF3 and NF-kB contributes to UV radiation-induced immune suppression
Authors: W Wang, NM Chapman, B Zhang, M Li, M Fan, RN Laribee, MR Zaidi, LM Pfeffer, H Chi, ZH Wu
Cancer Res., 2019-02-08;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1
Authors: N Zhang, Y Dou, L Liu, X Zhang, X Liu, Q Zeng, Y Liu, M Yin, X Liu, H Deng, D Song
EBioMedicine, 2019-01-31;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: ICC -
HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity
Authors: H Wang, H Yao, C Li, H Shi, J Lan, Z Li, Y Zhang, L Liang, JY Fang, J Xu
Nat. Chem. Biol., 2018-11-05;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry, ICC -
Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients
Authors: A Osa, T Uenami, S Koyama, K Fujimoto, D Okuzaki, T Takimoto, H Hirata, Y Yano, S Yokota, Y Kinehara, Y Naito, T Otsuka, M Kanazu, M Kuroyama, M Hamaguchi, T Koba, Y Futami, M Ishijima, Y Suga, Y Akazawa, H Machiyama, K Iwahori, H Takamatsu, I Nagatomo, Y Takeda, H Kida, EA Akbay, PS Hammerman, KK Wong, G Dranoff, M Mori, T Kijima, A Kumanogoh
JCI Insight, 2018-10-04;3(19):.
Species: Human
Sample Types: Plasma
Applications: ELISA (Capture) -
Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer
Authors: B Shao, CW Li, SO Lim, L Sun, YJ Lai, J Hou, C Liu, CW Chang, Y Qiu, JM Hsu, LC Chan, Z Zha, H Li, MC Hung
Am J Cancer Res, 2018-09-01;8(9):1837-1846.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Authors: CW Li, SO Lim, EM Chung, YS Kim, AH Park, J Yao, JH Cha, W Xia, LC Chan, T Kim, SS Chang, HH Lee, CK Chou, YL Liu, HC Yeh, EP Perillo, AK Dunn, CW Kuo, KH Khoo, JL Hsu, Y Wu, JM Hsu, H Yamaguchi, TH Huang, AA Sahin, GN Hortobagyi, SS Yoo, MC Hung
Cancer Cell, 2018-02-12;33(2):187-201.e10.
Species: Human
Sample Types: Whole Cells
Applications: ICC -
Rapid PD-L1 detection in tumors with PET using a highly specific peptide
Authors: Samit Chatterjee
Biochem. Biophys. Res. Commun, 2016-12-24;0(0):.
Applications: Bioassay -
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Nat Commun, 2016-08-30;7(0):12632.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers
Nature, 2016-05-23;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
B7-H1 enhances proliferation ability of gastric cancer stem-like cells as a receptor.
Authors: Yang Y, Wu K, Zhao E, Li W, Shi L, Xie G, Jiang B, Wang Y, Li R, Zhang P, Shuai X, Wang G, Tao K
Oncol Lett, 2015-02-10;9(4):1833-1838.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients.
Authors: Melendreras S, Martinez-Camblor P, Menendez A, Bravo-Mendoza C, Gonzalez-Vidal A, Coto E, Diaz-Corte C, Ruiz-Ortega M, Lopez-Larrea C, Suarez-Alvarez B
PLoS ONE, 2014-12-05;9(12):e113396.
Species: Human
Sample Types: Serum
Applications: ELISA (Standard) -
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
Authors: Steidl C, Shah SP, Woolcock BW
Nature, 2011-03-02;471(7338):377-81.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Authors: Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W, Stankevich E, Pons A, Salay T, McMiller T, Gilson M, Wang C, Selby M, Taube J, Anders R, Chen L, Korman A, Pardoll D, Lowy I, Topalian S
J Clin Oncol, 2010-06-01;28(19):3167-75.
Species: Human
Sample Types: Serum
Applications: ELISA (Capture) -
Cross-linking of B7-H1 on EBV-transformed B cells induces apoptosis through reactive oxygen species production, JNK signaling activation, and fasL expression.
Authors: Kim YS, Park GB, Lee HK, Song H, Choi IH, Lee WJ, Hur DY
J. Immunol., 2008-11-01;181(9):6158-69.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Programmed Death-1: from gene to protein in autoimmune human myasthenia gravis.
Authors: Sakthivel P, Ramanujam R, Wang XB, Pirskanen R, Lefvert AK
J. Neuroimmunol., 2007-11-26;193(1):149-55.
Applications: ELISA (Standard) -
Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis.
Authors: Wan B, Nie H, Liu A, Feng G, He D, Xu R, Zhang Q, Dong C, Zhang JZ
J. Immunol., 2006-12-15;177(12):8844-50.
Species: Human
Sample Types: N/A, Whole Cells
Applications: Bioassay, ELISA (Standard)
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human PD-1 Fc Chimera Protein, CF
Average Rating: 4.7 (Based on 10 Reviews)
Have you used Recombinant Human PD-1 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Cells expressing a negative control (left) or hPD-L1 mCherry (right) were treated with 0.25 ug of hPD-1 hIgG1. Cells were analyzed by flow cytometry with binding detected using an anti-human 488 secondary antibody.
Sorry that I just rate the catalog based on my alike recombinant PD1 peptide. I have one question for the peptide. Owing the Ig like peptide with Fc fragment. So when we detect it binding to PDL1 on cell assay, it is difficult to get definite conclusion if it is PDL1 binding or others.
My protocol is as below:
-Cells with PDL1 high level was treated by PD1 like peptide,
-4degree 1hr
-collected and lysis
-WB by anti-IgG to Fc recognization.
Result: weak signal. you don't know if it is non-specific binding
***Bio-Techne Response: Thank you for reviewing our product. We are sorry to hear that this antibody did not perform as expected. We have been in touch with the customer to resolve this issue according to our Product Guarantee and to the customer’s satisfaction.***
